Mydecine Archives

StaffSeptember 18, 2023

The Daily Hit is a recap of the top financial news stories for Sept. 18, 2023. On the Site Workers Strike at Curaleaf Arizona Dispensary Some workers at a Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) dispensary in Phoenix have gone on strike as of Friday, in an attempt they say to force company executives to the bargaining […]

John SchroyerSeptember 18, 2023

Psychedelics firm Mydecine Innovations Group Inc. (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), which is still in the pre-revenue stage, announced a plan to offer 18.75 million additional shares for distribution at 20 cents apiece, in an attempt to raise $3.75 million. The offering, outlined in a prospectus filed with Canadian securities regulators late last week, the offering was […]

Debra BorchardtAugust 15, 2023

Mydecine Innovations Group (OTC: MYCOF) released the barest of financial results for the quarter ending June 30, 2023. There is no revenue to report. The net loss attributable to common stockholders was $3.18 million, from operations, or a basic and diluted loss per share of $(0.13). For the same period in 2022, the loss from […]

John SchroyerMay 16, 2023

The Canadian psychedelics company reported a loss of C$7.6 million for the first quarter.

Debra BorchardtMarch 7, 2023

Some consultants are getting paid in stock instead of cash.

Debra BorchardtSeptember 2, 2022

Mydecine sells Mindleap and gets a much-needed cash infusion.

Debra BorchardtAugust 17, 2022

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) has burned through its cash and is closing its research operations in Denver Colorado. The psilocybin company reported financial results for the six months ending June 30, 2022, with a net loss of $8.09 million or a basic and diluted loss per share of $(1.31). Mydecine said it […]

Dave HodesApril 8, 2022

While the numbers on the spreadsheets of psychedelics companies are still to be taken with a grain of salt, given that this is an emerging biotechnology industry still in the drug development stage, there are encouraging signs that perhaps 2022 could be the beginning of a rebound. Some of the financial downbeat news from 2021 […]

StaffJune 8, 2021

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) reports that its R&D team has discovered over 40 compounds with pharmacological potential in mushrooms. Mydecine said that it has screened over 25 mushroom species, including various varieties of p. cubensis, and has selected and analyzed over 40 unique compounds found throughout the various species. Of these compounds, a […]

Debra BorchardtApril 7, 2021

Mydecine Innovations Group (OTC: MYCOF) has announced its four lead novel drug candidates as it prepares for its Pre-Investigational New Drug (IND) meetings with the FDA and Health Canada. Mydecine said it believes that these drug candidates are unique and patentable in the United States and Canada and has received advice from counsel confirming such […]

Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC

Functional Mushrooms Move Into Mainstream as Wellness Trend Grows

In other news

The Daily Hit: January 4, 2024

Connecticut Attorney General Tells Unlicensed Cannabis Events Company to Stop

Testing Concerns Lead to Quarantine for 70% of Mississippi MMJ Goods

Tag: Mydecine

The Daily Hit: September 18, 2023

Mydecine Attempts to Raise Money With New Prospectus

Mydecine Releases Scant Financial Information

Mydecine Loss Rate Increases, Only C$10k Left On Hand

Psychedelic Companies Tripping Over Debt Payments

Mydecine Sells Mindleap For C$4 Million

Psilocybin Company Mydecine Is Down To $300k In Cash

Has a Financial Rebound for the Psychedelics Industry Begun?

Mydecine Discovers 40 New Compounds In Mushrooms

Mydecine Names Drug Candidates For FDA Meetings

The Daily Hit - TEST TEST TEST

Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC

Functional Mushrooms Move Into Mainstream as Wellness Trend Grows

Get the latest cannabis news delivered right to your inbox